We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Merck KGaA (MKGAF) in Q2 Earnings?
Read MoreHide Full Article
Merck KGaA (MKGAF - Free Report) is scheduled to report second-quarter 2016 earnings results on Aug 4. Let’s see how things are shaping up for this quarter.
The company reports results under three business sectors – Healthcare, Life Science and Performance Materials. Strong performance at Healthcare and Life Science were the key catalysts behind sales growth last quarter and this should continue to boost sales in the to-be-reported quarter as well.
The Healthcare division is expected to be driven by sales growth of products like Erbitux, Gonal-f, and Euthyrox. However, we remain concerned regarding Rebrif sales, which are being dampened by negative foreign exchange fluctuations in Latin America.
The Life Science division witnessed solid organic sales growth last quarter driven by continued demand for its products and the integration of the Sigma-Aldrich business. This trend should continue in the second quarter as well.
Performance Materials is projected to be driven by the acquisitions of AZ Electronic Materials and Sigma-Aldrich Hitech business.
The company expects slight organic sales growth in 2016. Group net sales are anticipated in the range of €14.8–€ 15 billion. Backed by the Sigma-Aldrich acquisition, Merck KGaA expects a positive portfolio effect on sales in the low double-digit percentage range during the year. However, unfavorable foreign exchange is projected to impact sales by 3–5%.
Meanwhile, Merck KGaA, in collaboration with Pfizer Inc. (PFE - Free Report) , is evaluating avelumab in several phase III studies for indications such as gastric cancer, platinum-resistant/refractory ovarian cancer, bladder cancer and advanced renal cell carcinoma.
Last month, the European Medicines Agency (EMA) accepted to review the company’s Marketing Authorisation Application (MAA) for cladribine for the treatment of relapsing-remitting multiple sclerosis. The company had discontinued the development of cladribine tablets in 2011 after certain regulatory authorities raised concerns related to the candidate’s benefit-risk profile. The company was, however, allowed to complete a few large studies on the candidate and collect additional safety information in a long-term registry.
During its second-quarter call, investors are expected to focus on the company's approved products and its progress on avelumab. We also expect the company to shed further light on its progress with cladribine during the upcoming results.
Here are a couple of health care stocks that you may want to consider, as our model shows that they have the right combination of elements – a positive Zacks Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) – to post an earnings beat this quarter.
Ironwood Pharmaceuticals (IRWD - Free Report) has an Earnings ESP of +13.33% and a Zacks Rank #2. The company is expected to report earnings on Aug 4.
Impax Laboratories has an Earnings ESP of +3.03% and a Zacks Rank #2. The company is scheduled to report results on Aug 9.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What's in Store for Merck KGaA (MKGAF) in Q2 Earnings?
Merck KGaA (MKGAF - Free Report) is scheduled to report second-quarter 2016 earnings results on Aug 4. Let’s see how things are shaping up for this quarter.
The company reports results under three business sectors – Healthcare, Life Science and Performance Materials. Strong performance at Healthcare and Life Science were the key catalysts behind sales growth last quarter and this should continue to boost sales in the to-be-reported quarter as well.
The Healthcare division is expected to be driven by sales growth of products like Erbitux, Gonal-f, and Euthyrox. However, we remain concerned regarding Rebrif sales, which are being dampened by negative foreign exchange fluctuations in Latin America.
The Life Science division witnessed solid organic sales growth last quarter driven by continued demand for its products and the integration of the Sigma-Aldrich business. This trend should continue in the second quarter as well.
Performance Materials is projected to be driven by the acquisitions of AZ Electronic Materials and Sigma-Aldrich Hitech business.
The company expects slight organic sales growth in 2016. Group net sales are anticipated in the range of €14.8–€ 15 billion. Backed by the Sigma-Aldrich acquisition, Merck KGaA expects a positive portfolio effect on sales in the low double-digit percentage range during the year. However, unfavorable foreign exchange is projected to impact sales by 3–5%.
Meanwhile, Merck KGaA, in collaboration with Pfizer Inc. (PFE - Free Report) , is evaluating avelumab in several phase III studies for indications such as gastric cancer, platinum-resistant/refractory ovarian cancer, bladder cancer and advanced renal cell carcinoma.
Last month, the European Medicines Agency (EMA) accepted to review the company’s Marketing Authorisation Application (MAA) for cladribine for the treatment of relapsing-remitting multiple sclerosis. The company had discontinued the development of cladribine tablets in 2011 after certain regulatory authorities raised concerns related to the candidate’s benefit-risk profile. The company was, however, allowed to complete a few large studies on the candidate and collect additional safety information in a long-term registry.
During its second-quarter call, investors are expected to focus on the company's approved products and its progress on avelumab. We also expect the company to shed further light on its progress with cladribine during the upcoming results.
MERCK KGAA Price
MERCK KGAA Price | MERCK KGAA Quote
Stocks That Warrant a Look
Here are a couple of health care stocks that you may want to consider, as our model shows that they have the right combination of elements – a positive Zacks Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) – to post an earnings beat this quarter.
Ironwood Pharmaceuticals (IRWD - Free Report) has an Earnings ESP of +13.33% and a Zacks Rank #2. The company is expected to report earnings on Aug 4.
Impax Laboratories has an Earnings ESP of +3.03% and a Zacks Rank #2. The company is scheduled to report results on Aug 9.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>